The Clinical Validation Of Objective Measurement Of Movement In Parkinson’s Disease

Author:Malcolm Horne, Katya Kotschet and Sarah McGregor
Volume Info:Volume 2 Issue 1
Article Information

Volume 2 Issue 1 , pages 16-23
Received – 28 February 2016, Accepted – 06 April 2016

 


Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville Victoria 3010 Australia.

entre for Clinical Neurosciences and Neurological Research, St Vincent’s Hospital Melbourne, Fitzroy, Victoria Australia 3065.

 


Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville Victoria 3010 Australia.

entre for Clinical Neurosciences and Neurological Research, St Vincent’s Hospital Melbourne, Fitzroy, Victoria Australia 3065.

 


entre for Clinical Neurosciences and Neurological Research, St Vincent’s Hospital Melbourne, Fitzroy, Victoria Australia 3065.

 

Corresponding Author: Malcolm Horne – malcolm.horne@florey.edu.au,

Katya Kotschet – Katya.KOTSCHET@svha.org.au,

Sarah McGregor – Sarah.MCGREGOR@svha.org.au

Abstract:


Introduction
Home based objective measures of bradykinesia and dyskinesia will be important in managing Parkinsons Disease (PD).The Aim of this paper was to further validate the Parkinsons Kinetigraph system as a tool for measuring bradykinesia and dyskinesia by examining its capacity capture the effect of therapeutic interventions, detect bradykinesia and asymmetry in a newly diagnosed patients, and correlates with relevant clinical scales and its repeat reliability.

Methods
Data was obtained from patients who had used the Parkinsons Kinetigraph as part of routine clinical care or in other unrelated studies and for whom clinical scales (where relevant) were also available. The results are presented as a separate studies.

Results
A change in dyskinesia following insertion of Deep Brain Stimulators was observed and was commensurate to the changes obtained by clinical scales. A consistent change in bradykinesia and dyskinesia following levodopa was measured in patients with fluctuating PD. Bradykinesia was measured in newly diagnosed and differed from controls with a Sensitivity of 100% and Selectivity of 83% (Area under Receiver operator curve of 0.96). Asymmetry was greater than controls in 56%, which broadly correlated with differences found with clinical scales. We found that five days of recording produced a consistent bradykinesia score with a 6% standard error.

Conclusion
In this paper we provide data from a series of studies that show that the PKG system provide further validation that it could be used in routine care of Parkinsons Disease (PD).

 

Keywords:


Parkinson’s Disease, objective measures, dyskinesia, bradykinesia, ambulatory monitoring.

0 Comments

Newsletter

Keep up to date with our latest
articles and journals